In recent years, the intricate relationship between chronic inflammatory conditions and neurodegenerative diseases has increasingly become a focal point of biomedical research. One of the most intriguing intersections lies in the potential link between inflammatory bowel disease (IBD) and Alzheimer’s disease (AD). Both diseases involve complex immune system dynamics, with myeloid cells—such as monocytes, macrophages, and microglia—playing critical roles in orchestrating immune responses. A recent comprehensive genetic study published in Genes & Immunity sheds new light on how susceptibility loci for IBD and AD might intersect or diverge in their impact on immune pathways, and what implications this has for understanding disease mechanisms and therapeutic interventions.
Myeloid cells are pivotal in both innate and adaptive immunity, fulfilling roles that range from antigen presentation to cytokine secretion and tissue repair. Microglia, the resident immune cells of the central nervous system (CNS), have attracted particular attention in Alzheimer’s research due to their involvement in the brain’s response to amyloid plaques and neuroinflammation. In parallel, peripheral myeloid populations like monocytes and macrophages are central to the pathology of inflammatory bowel diseases including Crohn’s disease (CD) and ulcerative colitis (UC). Understanding how these cells and their related genetic pathways intertwine in IBD and AD could unravel novel aspects of disease susceptibility and progression.
Leveraging genome-wide association studies (GWAS) has become an indispensable method in unraveling the polygenic nature of complex diseases. The recent study systematically interrogated GWAS data for both IBD and AD to identify whether shared genetic underpinnings exist that influence the function of myeloid cells. By integrating expression Quantitative Trait Locus (eQTL) data specific to microglia and monocytes, the researchers aimed to connect genetic variants with their functional consequences in relevant immune subsets—thereby pinpointing biologically meaningful pathways that may contribute to disease risk.
.adsslot_YKTfIxwp8t{width:728px !important;height:90px !important;}
@media(max-width:1199px){ .adsslot_YKTfIxwp8t{width:468px !important;height:60px !important;}
}
@media(max-width:767px){ .adsslot_YKTfIxwp8t{width:320px !important;height:50px !important;}
}
ADVERTISEMENT
One of the study’s central findings was the distinct enrichment patterns of susceptibility loci: AD-associated genetic variants showed a greater enrichment in microglial eQTLs, whereas IBD-associated variants were predominantly enriched within monocyte eQTLs. This segregation suggests that although both diseases implicate myeloid cells, the specific subpopulations and molecular mechanisms underlying their genetic risk profiles differ significantly. Such divergence may reflect tissue-specific immune responses that are crucial for disease pathogenesis in the brain versus the gastrointestinal tract.
However, despite these differences, the genetic analysis uncovered subtle but intriguing connections between IBD susceptibility and Alzheimer’s disease. Mendelian randomization analyses, which infer causal relationships from genetic data, indicated that genetically predicted IBD risk exerted a modest protective effect against AD, a finding that challenges the simplistic assumption of uniformly detrimental effects of systemic inflammation on neurodegeneration. This counterintuitive observation opens avenues for exploring how chronic gut inflammation might modulate systemic immune tone in ways that impact neurodegenerative pathways.
Focusing more closely on Crohn’s disease, the data revealed an association of CD susceptibility variants with increased amyloid-beta accumulation—a hallmark pathological feature of Alzheimer’s disease. The beta coefficient (β = 7.14) from the analysis underscores a modest but statistically significant link, suggesting that specific inflammatory mechanisms driven by Crohn’s disease risk alleles may influence amyloid deposition in the brain. Such findings underscore the complexity within IBD subtypes and their differential impacts on neurodegenerative processes.
Conversely, ulcerative colitis susceptibility was connected with increased deposition of transactive response DNA-binding protein 43 (TDP-43), a protein mainly associated with neurodegenerative diseases such as frontotemporal lobar degeneration and amyotrophic lateral sclerosis but also recognized in AD pathology. The study’s quantitative analyses found a strong association (β = 7.58, p = 6.11 × 10−4), suggesting a unique molecular linkage between UC susceptibility and TDP-43 pathology. This highlights that diverse inflammatory pathways across different IBD forms may differentially influence distinct molecular events in Alzheimer’s disease.
These nuanced differences in how CD and UC genetic susceptibility relate to different AD pathologies—amyloid beta accumulation versus TDP-43 deposition—reinforce the notion that the gut-brain axis is multifaceted and that systemic inflammation’s effect on neurodegeneration cannot be generalized simply as harmful or protective. Instead, these observations compel a deeper exploration of the immunogenetic crosstalk that may tailor disease risk in a highly context-dependent manner.
The integration of microglial and monocyte eQTL data to connect GWAS variants with gene expression further elucidates functional pathways that could be targeted therapeutically. In Alzheimer’s disease, microglia are implicated in a range of processes from synaptic pruning to cytokine production and clearance of neurotoxic proteins. The enrichment of AD loci in microglial regulatory elements reinforces the centrality of these cells in disease etiology and underscores microglia as promising targets for intervention.
Meanwhile, the predominance of monocyte eQTL enrichment in IBD loci reflects the known contribution of peripheral myeloid cells to the chronic intestinal inflammation characteristic of Ulcerative Colitis and Crohn’s disease. These cells perpetuate mucosal damage through pro-inflammatory cytokine release and recruitment of other immune effectors. The dissociation between microglial and monocyte genetic signals not only mirrors tissue-specific immune landscapes but also hints at compartmentalized therapeutic strategies.
This study’s findings are also significant in the broader context of precision medicine. The association of IBD susceptibility variants with modest protective or risk-modifying effects in AD underlines the complexity of immune-mediated influences on neurodegeneration. It suggests that interventions aimed at modulating systemic or gut inflammation could have unintended or variable consequences on Alzheimer’s pathology depending on the underlying genetic profile and disease subtypes.
Furthermore, by uncovering specific genetic correlations with distinct pathological markers such as amyloid beta and TDP-43, the research paves the way for biomarker-driven therapeutic stratification. Identifying individuals with genetic risk profiles linking their gastrointestinal inflammatory disease with particular neurodegenerative signatures may enable earlier prediction, monitoring, and tailored treatments aiming at both peripheral and central immune mechanisms.
The complexity emphasized by this study also cautions against oversimplification in the evolving field of neuroimmunology. While inflammation is generally regarded as a driver of neurodegenerative damage, these genetic insights reveal that certain inflammatory disease backgrounds may confer nuanced effects—sometimes protective, sometimes promotive—on different facets of AD pathology.
In summary, this pivotal research elucidates that although inflammatory bowel diseases and Alzheimer’s disease share the involvement of myeloid immune cells, the genetic risk landscapes and related myeloid cell populations implicated in each disorder are largely distinct. The subtleties of these genetic interactions provide compelling evidence for a surprisingly modest yet significant contribution of IBD susceptibility to AD risk and pathology. Importantly, the contrasting effects of Crohn’s disease and ulcerative colitis susceptibility on amyloid and TDP-43 deposition in the brain emphasize the need for precision immunogenetic approaches to unravel and eventually manipulate these disease pathways.
As the scientific and medical communities continue to explore the interplay between chronic peripheral inflammation and central nervous system degeneration, studies such as this one highlight the imperative to dissect these relationships at the molecular and cellular levels. Going forward, the integration of genetic, transcriptomic, and functional data from both peripheral immune compartments and brain-resident immune cells will be crucial for developing innovative therapies that address the multifaceted etiology of Alzheimer’s disease in patients with or without comorbid inflammatory bowel disease.
Advancements from this research promise to enhance our understanding of how gut inflammation may influence brain health and open the door to novel therapeutic strategies that harmonize immune regulation across organ systems. The potential of targeting myeloid cell pathways to mitigate or prevent Alzheimer’s progression in the context of inflammatory bowel disease is an exciting frontier emerging from these genetic insights, meriting intensified investigation and clinical translation.
Subject of Research:
Inflammatory bowel disease and Alzheimer’s disease genetic associations mediated through myeloid cell pathways.
Article Title:
Genetic insights into the association between inflammatory bowel disease and Alzheimer’s disease.
Article References:
Zeng, L., White, C.C., Bennett, D.A. et al. Genetic insights into the association between inflammatory bowel disease and Alzheimer’s disease. Genes Immun (2025). https://doi.org/10.1038/s41435-025-00344-4
Image Credits: AI Generated
DOI:
https://doi.org/10.1038/s41435-025-00344-4
Tags: brain response to amyloid plaqueschronic inflammatory conditions and neurodegenerative diseasescytokine secretion in immune pathwaysGenetic links between IBD and Alzheimer’sgenetic pathways in chronic diseasesimmune system dynamics in IBD and ADinflammatory bowel disease mechanismsmicroglia’s role in Alzheimer’smonocytes and macrophages in disease pathologymyeloid cells in immune responsessusceptibility loci for inflammatory bowel diseasetherapeutic implications for neurodegenerative diseases
